EUVIMEDEUVIMED entdecken
VergleichsstudieMetaanalyseSystematische ÜbersichtOpen Access · CC BY 4.0

Efficacy of Potassium-Competitive Acid Blockers Versus Proton Pump Inhibitors in Eradication Regimens for Clarithromycin-Resistant Helicobacter pylori: A Systematic Review and Meta-Analysis

Dmitrii N Andreev iD, Alsu R Khurmatullina iD, Dmitry S Bordin iD, Andrey V Zaborovsky, Philipp S Sokolov iD, Yury A Kucheryavyy iD, Petr A Beliy, Igor V Maev

Pathogens · 2026

DOI: 10.3390/pathogens15090986 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Pathogens, 2026. Verfasst von Dmitrii N Andreev und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Disease Propaedeutics and Gastroenterology, Russian University of Medicine, 127473 Moscow, Russia. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Clarithromycin, Drug Resistance, Bacterial, Helicobacter Infections. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Clarithromycin resistance represents the primary obstacle to the success of conventional proton pump inhibitor (PPI)-based triple therapy for Helicobacter pylori (H. pylori) eradication. Potassium-competitive acid blockers (P-CABs) offer faster and more potent acid suppression, which may enhance the efficacy of eradication regimens in this resistant population. The present study aimed to systematically evaluate the comparative efficacy of P-CAB-based versus PPI-based eradication regimens specifically in adult patients with documented clarithromycin-resistant H. pylori infection.

Methods

This systematic review and meta-analysis was conducted in accordance with the PRISMA 2020 guidelines. The protocol was prospectively registered in PROSPERO (CRD420261407870). A systematic literature search was performed in Embase; MEDLINE/PubMed; CENTRAL; and Web of Science for articles published from 1 February 2015 to 31 March 2026. The included evidence comprised randomized and non-randomized comparative studies, as well as non-comparative studies. The primary outcome was the H. pylori eradication rate. Pooled risk ratios (RRs) with 95% confidence intervals (CIs) were calculated using a random-effects model (DerSimonian–Laird method). Risk of bias was assessed using RoB 2 for randomized comparative studies, ROBINS-I for non-randomized comparative studies, and the JBI Critical Appraisal Checklist for Case Series for non-comparative studies.

Results

A total of 20 unique publications were included; 12 contributed data to the comparative analysis and 9 contributed data to the non-comparative single-arm analysis, with one publication contributing to both analyses. Across the 12 comparative studies, successful eradication was achieved in 464 of 621 patients (74.7%) receiving P-CAB-based regimens and in 301 of 571 patients (52.7%) receiving PPI-based comparators. P-CAB-based regimens were associated with a significantly higher probability of successful eradication compared with PPIs (RR, 1.42; 95% CI, 1.14–1.76; p < 0.00001). Subgroup analysis according to the P-CAB agent demonstrated that vonoprazan-based regimens exhibited the strongest comparative effect (RR, 1.78; 95% CI, 1.55–2.04), while tegoprazan-based regimens also remained superior (RR, 1.26; 95% CI, 1.04–1.54). The benefit of P-CABs was most pronounced in the clarithromycin-containing triple therapy subgroup (RR, 1.79; 95% CI, 1.55–2.07).

Conclusions

P-CAB-based eradication regimens are significantly more effective than PPI-based comparators in patients with clarithromycin-resistant H. pylori infection. Further well-designed studies are warranted to determine the optimal antibiotic combinations, treatment durations, and regional applicability of these regimens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsClarithromycinDrug Resistance, BacterialHelicobacter InfectionsHelicobacter pyloriProton Pump InhibitorsHumansDrug Therapy, CombinationTreatment Outcome

Stichwörter der Autor:innen

Helicobacter pyloriP-CABclarithromycin resistanceeradication therapymeta-analysispotassium-competitive acid blockerssystematic reviewtegoprazanvonoprazan

Substanzen

Anti-Bacterial AgentsClarithromycinProton Pump Inhibitors

Autor:innen und Institutionen

  • Department of Internal Disease Propaedeutics and Gastroenterology, Russian University of Medicine, 127473 Moscow, Russia.
  • I.M. Sechenov First Moscow State Medical University, 119991 Moscow, Russia.
  • Department of Pancreatic, Biliary and Upper Digestive Tract Disorders, A. S. Loginov Moscow Clinical Scientific Center, 111123 Moscow, Russia.
  • Department of General Medical Practice and Family Medicine, Tver State Medical University, 170100 Tver, Russia.
  • Department of Pharmacology, Russian University of Medicine, 127473 Moscow, Russia.
  • Ilyinskaya Hospital, 143421 Krasnogorsk, Russia.

ORCID-Profile: Dmitrii N Andreev, Alsu R Khurmatullina, Dmitry S Bordin, Philipp S Sokolov, Yury A Kucheryavyy

Zitieren

APA

Andreev, D. N., Khurmatullina, A. R., Bordin, D. S., Zaborovsky, A. V., Sokolov, P. S., Kucheryavyy, Y. A., Beliy, P. A., & Maev, I. V. (2026). Efficacy of Potassium-Competitive Acid Blockers Versus Proton Pump Inhibitors in Eradication Regimens for Clarithromycin-Resistant Helicobacter pylori: A Systematic Review and Meta-Analysis. Pathogens. https://doi.org/10.3390/pathogens15090986

Vancouver

Andreev DN, Khurmatullina AR, Bordin DS, Zaborovsky AV, Sokolov PS, Kucheryavyy YA, et al. Efficacy of Potassium-Competitive Acid Blockers Versus Proton Pump Inhibitors in Eradication Regimens for Clarithromycin-Resistant Helicobacter pylori: A Systematic Review and Meta-Analysis. Pathogens. 2026. doi:10.3390/pathogens15090986

BibTeX
@article{Andreev2026,
  author = {Andreev, Dmitrii N and Khurmatullina, Alsu R and Bordin, Dmitry S and Zaborovsky, Andrey V and Sokolov, Philipp S and Kucheryavyy, Yury A and Beliy, Petr A and Maev, Igor V},
  title = {Efficacy of Potassium-Competitive Acid Blockers Versus Proton Pump Inhibitors in Eradication Regimens for Clarithromycin-Resistant Helicobacter pylori: A Systematic Review and Meta-Analysis},
  journal = {Pathogens},
  year = {2026},
  doi = {10.3390/pathogens15090986}
}
Kostenlos starten →